NCT06966583View on ClinicalTrials.gov

NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

November 30, 2027

Conditions
Solid TumorNon Small Cell Lung Cancer
Interventions
DIETARY_SUPPLEMENT

NAD supplement

NAD supplement NMN：NMN12000 GeneHarbor

RADIATION

Radiotherapy

Low Dose Radiotherapy or Stereotactic Ablative Radiotherapy or Conventional Radiotherapy

DRUG

Immunotherapy

PD-1 inhibitor

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER